OLK NASDAQ

Olink Holding AB (publ) offers a comprehensive suite of products and services tailored for life science research institutions, including academic bodies, government entities, biopharmaceutical companies, and biotechnology firms. The company's product lines include Olink Explore, which is designed to aid research in critical areas such as cardiovascular and metabolic health, oncology, neurology, and inflammation. Additionally, it features the Olink Target product line and the Olink Focus product line, the latter providing bespoke solutions for clients who have already pinpointed specific proteins or protein signatures for their studies. Beyond these, Olink supplies the Signature Q100, a dedicated platform for qPCR (quantitative Polymerase Chain Reaction) readouts. Its service portfolio encompasses Olink Analysis, offering end-to-end support from study design and expert consultation to sample preparation, assay execution, and stringent quality control of data, complemented by bioinformatics services. For data management and analysis, Olink provides the normalized protein expression (NPX) Manager, a specialized software tool enabling users to import data, validate its quality, and normalize findings in preparation for statistical analysis. Furthermore, Olink Insight serves as a cloud-based platform for visualizing and statistically analyzing NPX data. Olink Holding AB (publ) markets and sells its offerings worldwide through its proprietary direct sales force, reaching customers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Established in 2004 and based in Uppsala, Sweden, the company underwent a name change in January 2021 from its former identity, Knilo HoldCo AB, to its current designation. It operates as a subsidiary of Summa Equity Holding AB.